Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.34 USD | -4.30% | -5.38% | -19.32% |
May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 101M |
---|---|---|---|---|---|
Net income 2024 * | -102M | Net income 2025 * | -115M | EV / Sales 2024 * | - |
Net cash position 2024 * | 159M | Net cash position 2025 * | 89.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-1.36
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | -4.30% | ||
1 week | -5.38% | ||
Current month | -8.24% | ||
1 month | -22.33% | ||
3 months | -40.25% | ||
6 months | +19.29% | ||
Current year | -19.32% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 430 M€ | -.--% | ||
0.00% | 234 M€ | +5.72% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.34 | -4.30% | 46,958 |
24-05-16 | 3.49 | +0.29% | 43,536 |
24-05-15 | 3.48 | -4.40% | 67,528 |
24-05-14 | 3.64 | +3.12% | 100,072 |
24-05-13 | 3.53 | 0.00% | 58,248 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.32% | 101M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- RLMD Stock